| Quarterly Financials | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 121 | 184 | 89 | 66 | 71 | 57 | 57 | 70 | 68 | 70 | 79 | 93 | 80 | 90 | 85 | 117 | 112 |
| Expenses | 73 | 100 | 64 | 48 | 52 | 40 | 41 | 74 | 54 | 54 | 61 | 78 | 63 | 70 | 67 | 90 | 87 |
| EBITDA | 49 | 84 | 25 | 18 | 18 | 17 | 16 | -4 | 14 | 16 | 17 | 14 | 18 | 20 | 18 | 27 | 25 |
| Operating Profit % | 40 % | 45 % | 28 % | 25 % | 26 % | 28 % | 27 % | -7 % | 20 % | 22 % | 21 % | 15 % | 22 % | 22 % | 21 % | 22 % | 22 % |
| Depreciation | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 3 |
| Profit Before Tax | 46 | 80 | 22 | 14 | 14 | 12 | 10 | -10 | 7 | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 |
| Tax | 11 | 21 | 6 | 4 | 4 | 2 | 3 | -2 | 2 | 2 | 2 | 2 | 3 | 4 | 3 | 5 | 5 |
| Net Profit | 34 | 60 | 16 | 11 | 11 | 9 | 7 | -7 | 5 | 6 | 8 | 4 | 8 | 9 | 9 | 15 | 12 |
| EPS in ₹ | 32.96 | 57.33 | 15.20 | 9.97 | 9.99 | 8.82 | 6.82 | -7.23 | 5.10 | 5.99 | 7.39 | 4.08 | 8.04 | 8.15 | 8.21 | 13.95 | 11.49 |
Kwality Pharmaceuticals
Kwality Pharmaceuticals
914.65
+21.05
(2.36%)
Key Fundamentals
Market Cap
949.04 Cr
EPS
38.36
PE Ratio
21.38
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
1,235.00
52 Week Low
596.05
PB Ratio
3.52
Debt to Equity
0.43
Sector
Pharmaceuticals Actual
Company News
View All News
Kwality Pharmaceutical Ltd has received product registration for Bleomycin 15 IU per vial in Mexico, expanding its oncology product portfolio in regulated markets. Bleomycin is an anti-cancer medicine used to treat Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. The company projects a business potential of around 1 million USD in the first year, with supplies expected to commence before the end of Q2FY26. This approval strengthens the company's expansion into highly regulated markets and reinforces its commitment to delivering quality oncology products globally.
Kwality Pharmaceuticals Board Approves Multiple Director Re-appointments and 42nd AGM Arrangements
Aug 16, 2025
Aug 16, 2025Kwality Pharmaceuticals' Board of Directors approved several key decisions for their 42nd Annual General Meeting scheduled for September 9, 2025. The Board approved re-appointments of multiple directors for five-year terms from January 16, 2026 to January 15, 2031, including Managing Director Ramesh Arora, Whole Time Directors Ajay Kumar Arora, Anju Arora, and Geeta Arora, and Independent Director Kartik Kapur for his second term. The Board also approved regularization of Vinod Kumar Sharma as Additional Independent Director and appointed M/s Rishi Mittal & Associates as Secretarial Auditors for five years. E-voting will be available from September 6-8, 2025, with book closure from September 2-9, 2025. All director re-appointments and auditor appointment are subject to shareholder approval at the AGM.
Kwality Pharmaceuticals Limited reported strong quarterly results with consolidated revenue rising 39.8% year-on-year from ₹80 crore to ₹111.8 crore. EBITDA grew 39% to ₹24.6 crore while maintaining stable margins at around 22%. Net profit increased 43% from ₹8.3 crore to ₹11.9 crore. The company completed a regulatory audit in Zimbabwe and received multiple new product registrations during the quarter. Key upcoming milestones include an EU-GMP audit scheduled for October and a WHO-GMP inspection of their biologics facility later this year. The company is targeting ₹500 crore revenue for FY26 and continues expanding its international presence across over 70 countries with a portfolio exceeding 3,000 formulations.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,696.00 | #1 4,06,927.21 | 39.01 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 61.71 | |
6,596.50 | 1,75,116.35 | 75.90 | 9,712.00 | 18.67 | 2,191 | 26.74 | 72.60 | |
1,644.60 | 1,32,843.24 | 24.96 | 28,409.50 | 7.12 | 5,291 | 9.88 | 60.63 | |
3,623.10 | 1,22,622.17 | 60.69 | 11,539.40 | 6.99 | 1,911 | 19.91 | 53.74 | |
1,281.90 | 1,06,989.14 | #1 18.74 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.97 | |
1,011.65 | 1,01,795.66 | 21.36 | 23,511.00 | 18.55 | 4,615 | 2.60 | 45.37 | |
2,457.90 | 1,01,451.91 | 52.80 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 47.04 | |
1,951.00 | 89,112.81 | 23.85 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.82 | |
5,558.50 | 66,460.21 | 28.44 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.11 | |
1,104.50 | 64,149.54 | 19.03 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.87 |
Growth Rate
Revenue Growth
20.42 %
Net Income Growth
68.64 %
Cash Flow Change
22.66 %
ROE
42.98 %
ROCE
34.64 %
EBITDA Margin (Avg.)
0.32 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 354 | 394 | 447 |
| Fixed Assets | 13 | 13 | 17 | 20 | 29 | 43 | 57 | 92 | 121 | 139 | 146 |
| Current Assets | 25 | 38 | 53 | 75 | 75 | 89 | 106 | 228 | 207 | 243 | 284 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 |
| Investments | 1 | 2 | 3 | 5 | 4 | 3 | 4 | 0 | 0 | 0 | 0 |
| Other Assets | 24 | 37 | 51 | 71 | 72 | 87 | 102 | 237 | 219 | 255 | 302 |
| Total Liabilities | 37 | 51 | 71 | 96 | 105 | 133 | 166 | 341 | 354 | 394 | 447 |
| Current Liabilities | 17 | 27 | 42 | 62 | 61 | 68 | 78 | 140 | 126 | 152 | 170 |
| Non Current Liabilities | 1 | 3 | 4 | 6 | 8 | 20 | 28 | 21 | 29 | 20 | 15 |
| Total Equity | 19 | 21 | 25 | 29 | 36 | 45 | 60 | 180 | 199 | 223 | 262 |
| Reserve & Surplus | 15 | 17 | 20 | 19 | 27 | 36 | 51 | 171 | 190 | 214 | 254 |
| Share Capital | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 1 | 0 | 2 | -1 | -0 | 0 | 4 | 3 | -6 | -1 | 10 |
| Investing Activities | -1 | -3 | -7 | -6 | -12 | -18 | -23 | -63 | -48 | -26 | -29 |
| Operating Activities | 1 | -3 | 4 | -1 | 14 | 6 | 27 | 61 | 41 | 43 | 53 |
| Financing Activities | 1 | 6 | 5 | 5 | -2 | 12 | 1 | 6 | 1 | -17 | -14 |
Share Holding
| % Holding | Mar 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 54.13 % | 54.24 % | 54.24 % | 54.43 % | 54.45 % | 54.45 % | 54.45 % | 54.74 % | 54.74 % | 54.77 % | 54.77 % | 54.83 % | 54.83 % | 54.83 % | 54.83 % | 54.83 % | 54.83 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.02 % | 0.03 % | 0.32 % | 0.33 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 23.18 % | 25.38 % | 25.91 % | 26.29 % | 26.54 % | 26.25 % | 25.92 % | 26.27 % | 29.29 % | 31.64 % | 32.95 % | 31.70 % | 31.78 % | 32.78 % | 33.25 % | 33.39 % | 33.32 % |
| Others | 22.69 % | 20.38 % | 19.84 % | 19.28 % | 19.01 % | 19.30 % | 19.63 % | 18.99 % | 15.96 % | 13.58 % | 12.27 % | 13.47 % | 13.40 % | 12.38 % | 11.90 % | 11.47 % | 11.52 % |
| No of Share Holders | 148 | 168 | 379 | 581 | 1,049 | 4,198 | 5,376 | 6,211 | 6,943 | 6,291 | 5,786 | 5,695 | 5,273 | 7,487 | 8,947 | 9,420 | 10,115 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.6 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 12 Oct 2017 |  Bonus | 1:1 | 11 Oct 2017 | 0.00 | 0.00 |
| 24 Sept 2024 |  Annual General Meeting | NA | 24 Sept 2024 | 783.50 | 808.10 |
| 30 Oct 2024 |  Quarterly Result Announcement | NA | 30 Oct 2024 | 818.30 | 812.35 |
| 31 Jan 2025 | Quarterly Result Announcement | NA | 31 Jan 2025 | 892.20 | 870.20 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 719.45 | 809.00 |
| 11 Aug 2025 | Quarterly Result Announcement | NA | 11 Aug 2025 | 1,124.45 | 1,132.65 |
| 09 Sept 2025 | Annual General Meeting | NA | 09 Sept 2025 | 1,069.05 | 946.35 |
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 11, 2025
Oct 11, 2025Closure of Trading WindowSep 27, 2025
Sep 27, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 11, 2025
Sep 11, 2025Regularization And Reappointment Of Directors At AGMSep 10, 2025
Sep 10, 2025Appointment Of Secretarial Auditors Of The CompanySep 09, 2025
Sep 09, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Aug 22, 2025Kwality Pharma Receives Product Registration For Bleomycin 15 IU In Mexico For Sale And Distribution.Aug 18, 2025
Aug 18, 2025Notice Of 42Nd AGM Of The Company Scheduled To Be Held On 09Th September 2025Aug 16, 2025
Aug 16, 2025Reg. 34 (1) Annual Report.Aug 16, 2025
Aug 16, 2025 Intimation Of Book ClosureAug 16, 2025
Aug 16, 202542Nd Annual General Meeting (AGM) Of The Shareholders Of The Company Will Be Held On Tuesday The 09Th September 2025 At 12:00 Noon Through Video Conference (VC) / Other Audio Visual Means (OAVM)Aug 16, 2025
Aug 16, 2025Board Meeting Outcome for Board Meeting Outcome For Intimation Of AGMAug 16, 2025
Aug 16, 2025Standalone And Consolidated Unaudited Financial Results For The Quarter Ended June 30 2025Aug 11, 2025
Aug 11, 2025Board Meeting Outcome for Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended June 30 2025Aug 11, 2025
Aug 11, 2025Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended On 30Th June 2025.Aug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Resignation of DirectorJul 26, 2025
Jul 26, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 26, 2025
Jul 26, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Jul 14, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJun 05, 2025
Jun 05, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2025
May 27, 2025Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended 31St March 2025May 19, 2025
May 19, 2025Board Meeting Outcome for Audited Financial Results (Standalone And Consolidated) For The Quarter And Financial Year Ended 31St March 2025May 19, 2025
May 19, 2025Conclusion Of Regulatory Audit For ZimbabweMay 07, 2025
May 07, 2025Board Meeting Intimation for Considering The Standalone & Consolidated Audited Financial Results For The 4Th Quarter And Financial Year Ended On 31St March 2025May 06, 2025
May 06, 2025Disclosure Of Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated 26Th November 2018- Fund Raising By Issuance Of Debt Securities By Large CorporateApr 30, 2025
Apr 30, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Apr 09, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Kwality Pharmaceutical Limited Receives Product Registration Of Cyclophosphamide 1Gm In MexicoFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2025
Feb 04, 2025Integrated Filing (Financial)Jan 31, 2025
Jan 31, 2025 UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024Jan 31, 2025
Jan 31, 2025Board Meeting Outcome for SUBMISSION OF UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024Jan 31, 2025
Jan 31, 2025KWALITY PHARMA RECEIVED SFDA APPROVAL FOR ITS GENERAL INJECTABLES AND BETA LACTAM (UNIT 1 & 2 IN AMRITSAR).Jan 21, 2025
Jan 21, 2025Board Meeting Intimation for Declaring Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024 Along With Limited Review ReportJan 20, 2025
Jan 20, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 12, 2025
Jan 12, 2025Kwality Pharmaceutical Ltd Receives RCGM Approval To Advance For Pre-Clinical Studies Of Erythropoietin (10000 IU/Ml)Jan 02, 2025
Jan 02, 2025Intimation Under Regulation 30(6) Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 ('SEBI Listing Regulations') - Schedule Of Analyst/ Institutional Investor MeetingNov 27, 2024
Nov 27, 2024Kwality Received Its First Biological Product Permission For Manufacturing And Sale Of Pegylated-AsparaginaseNov 26, 2024
Nov 26, 2024Kwality Pharma Received The Approval For Leuprorelin Acetate For Injectable Suspension As A Site Variation From GreeceNov 06, 2024
Nov 06, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 06, 2024
Nov 06, 2024Board Meeting Outcome for Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024Oct 30, 2024
Oct 30, 2024Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2024Oct 30, 2024
Oct 30, 2024Board Meeting Intimation for Consider And Approve The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2024.Oct 22, 2024
Oct 22, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 11, 2024
Oct 11, 2024Closure of Trading WindowSep 29, 2024
Sep 29, 2024Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sSep 26, 2024
Sep 26, 2024Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.03% | 62 | 0.03% | 0.03% |
Technical Indicators
RSI(14)
Neutral 45.64
ATR(14)
Less Volatile 36.30
STOCH(9,6)
Neutral 31.48
STOCH RSI(14)
Overbought 88.98
MACD(12,26)
Bullish 3.03
ADX(14)
Very Strong Trend 51.74
UO(9)
Bearish 54.76
ROC(12)
Downtrend And Accelerating -2.33
WillR(14)
Neutral -43.58
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
